Meissa Vaccines has reported positive data from a clinical study of the intranasal live attenuated MV-012-968 vaccine against respiratory syncytial virus (RSV) in participants aged between six and 36 months.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,